Login Register Cart 0
Generic placeholder image

Current Drug Research Reviews

Editor-in-Chief

ISSN (Print): 2589-9775
ISSN (Online): 2589-9783

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Perspective

Is Daclatasvir a Suitable Substitute for Amphotericin B in the Treatment of Mucormycosis when Amphotericin B is Scarce?

Author(s): Pugazhenthan Thangaraju*, Sree Sudha Tanguturi Yella, Vijayakumar Arumugam Ramamurthy, Sivakumar Muthusamy, Lappathai Habib Mohamed Thameemul Ansari, Irfan Navabshan and Sajitha Venkatesan

Volume 16, Issue 1, 2024

Published on: 22 May, 2023

Page: [5 - 10] Pages: 6

DOI: 10.2174/2589977515666230430004013

Price: $65

conference banner
Abstract

Background: Mucormycosis has been infesting the universe for a while back, often with no prompt treatments. The disease devastation is spreading at an alarming rate. Many researchers are still hoping for a good potential drug that could help the healthcare system in this tussle. Molecular docking is an in silico tool that has gained popularity over the last few decades. Knowing the mechanism of enzymatic action is aided by imitating membrane protein actions in binding ligands.

Aim: The aim of this perspective is to determine whether an existing drug, daclatasvir, has antifungal activity.

Objective: The primary objective of this in silico study was to investigate the potential effects of the binding affinity of daclatasvir with the crucial protein (1XFF) of mucormycosis, as well as the binding pattern of the active site amino acids with the drug molecule.

Materials and Methods: To calculate the binding affinity of daclatasvir to the fungal protein 1XFF, Auto Dock Vina was used for molecular docking studies. The CDOCKER protocol was used to determine the receptor-ligand interaction by configuring various parameters.

Results: The docking energy of the ligand (daclatasvir) on the protein (1XFF) was found to be - 16.7216 kcal/mol, while the interaction energy was found to be -42.1314 kcal/mol.

Conclusion: The binding pattern completely alters the dynamics of the protein, resulting in the breakdown of the fungal wall. The vital protein (1XFF) of Rhizopus oryzae is proposed as a possible protein target for the non-structural protein 5A inhibitor/antiviral drug daclatasvir in this study.

« Previous Next »
[1]
Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000; 13(2): 236-301.
[http://dx.doi.org/10.1128/CMR.13.2.236] [PMID: 10756000]
[2]
Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: Pathophysiology, presentation, and management. Clin Microbiol Rev 2005; 18(3): 556-69.
[http://dx.doi.org/10.1128/CMR.18.3.556-569.2005] [PMID: 16020690]
[3]
Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clin Infect Dis 2005; 41(5): 634-53.
[http://dx.doi.org/10.1086/432579] [PMID: 16080086]
[4]
Gleissner B, Schilling A, Anagnostopolous I, Siehl I, Thiel E. Improved outcome of zygomycosis in patients with hematological diseases? Leuk Lymphoma 2004; 45(7): 1351-60.
[http://dx.doi.org/10.1080/10428190310001653691] [PMID: 15359632]
[5]
Khanna R, Cicinelli M, Gilbert S, Honavar S, Murthy GV. COVID-19 pandemic: Lessons learned and future directions. Indian J Ophthalmol 2020; 68(5): 703-10.
[http://dx.doi.org/10.4103/ijo.IJO_843_20] [PMID: 32317432]
[6]
Unnikrishnan R, Misra A. Infections and diabetes: Risks and mitigation with reference to India. Diabet Metabol Syndr 2020; 14(6): 1889e94.
[http://dx.doi.org/10.1016/j.dsx.2020.09.022]
[7]
Garg D. Coronavirus disease (Covid-19) Associated Mucormycosis (CAM): Case report and systematic review of literature. Mycopathologia 2021; 186(2): 289e98.
[8]
Jose A. Current understanding in the pathophysiology of SARSCoV-2- associated rhino-orbito-cerebral mucormycosis: A comprehensive review. J Maxillofacial Oral Surg 2021; 20(3): 1e8.
[9]
Alqarihi A, Gebremariam T, Gu Y, et al. GRP78 and integrins play different roles in host cell invasion during mucormycosis. MBio 2020; 11(3): e01087-20.
[http://dx.doi.org/10.1128/mBio.01087-20] [PMID: 32487760]
[10]
Dilek A, Ozaras R, Ozkaya S, Sunbul M, Sen EI, Leblebicioglu H. COVID-19-associated mucormycosis: Case report and systematic review. Travel Med Infect Dis 2021; 44: 102148-8.
[http://dx.doi.org/10.1016/j.tmaid.2021.102148] [PMID: 34454090]
[11]
Patel A, Agarwal R, Rudramurthy SM, et al. Multicenter epidemiologic study of coronavirus disease-associated mucormycosis, India. Emerg Infect Dis 2021; 27(9): 2349e59.
[12]
Sen M, Honavar SG, Bansal R, Sengupta S, Rao R, Kim U. Members of the Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC) study group. Epidemiology, clinical profile, management, and outcome of COVID-19- associated rhino-orbitalcerebral mucormycosis in 2826 patients in India - Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), report 1. Indian J Ophthalmol 2021; 69(7): 1670e92.
[13]
Sharma S, Grover M, Bhargava S, Samdani S, Kataria T. Post coronavirus disease mucormycosis: A deadly addition to the pandemic spectrum. J Laryngol 2021; 1-135(5): 442-7.
[14]
Farmakiotis D, Kontoyiannis DP. Mucormycoses. Infect Dis Clin North Am 2016; 30(1): 143-63.
[http://dx.doi.org/10.1016/j.idc.2015.10.011] [PMID: 26897065]
[15]
Steinbrink JM, Miceli MH. Mucormycosis. Infect Dis Clin North Am 2021; 35(1): 435-52.
[http://dx.doi.org/10.1016/j.idc.2021.03.009]
[16]
Izquierdo ACM, Cuesta I, Zaragoza O, Monzón A, Mellado E. In vitro activity of antifungals against Zygomycetes. Clin Microbiol Infect 2009; 15(5): 71-6.
[17]
Balasubramaniyan S, Irfan N, Senthilkumar C, Umamaheswari A, Puratchikody A. The synthesis and biological evaluation of virtually designed fluoroquinolone analogs against fluoroquinolone-resistant Escherichia coli intended for UTI treatment. New J Chem 2020; 44(31): 13308-18.
[http://dx.doi.org/10.1039/D0NJ00657B]
[18]
Belema M, Nguyen VN, Bachand C, et al. Hepatitis C virus NS5A replication complex inhibitors: The discovery of daclatasvir. J Med Chem 2014; 57(5): 2013-32.
[http://dx.doi.org/10.1021/jm401836p] [PMID: 24521299]
[19]
Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. J Fungi 2019; 5(1): 26.
[http://dx.doi.org/10.3390/jof5010026] [PMID: 30901907]
[20]
Ibrahim AS, Edwards JE, Filler SG. Zygomycosis. In: Dismukes WE, Pappas PG, Sobel JD, Eds. Clinical mycology. New York, NY: Oxford University Press 2003; pp. 241-51.
[21]
Ben-Ami R, Luna M, Lewis RE, Walsh TJ, Kontoyiannis DP. A clinicopathological study of pulmonary mucormycosis in cancer patients: Extensive angioinvasion but limited inflammatory response. J Infect 2009; 59(2): 134-8.
[http://dx.doi.org/10.1016/j.jinf.2009.06.002] [PMID: 19576639]
[22]
Mishra Y, Prashar M, Sharma D. Akash, Kumar VP, Tilak TVSVGK. Diabetes, COVID 19 and mucormycosis: Clinical spectrum and outcome in a tertiary care medical center in Western India. Diabetes Metab Syndr 2021; 15(4): 102196.
[http://dx.doi.org/10.1016/j.dsx.2021.102196] [PMID: 34246939]
[23]
Selarka L, Sharma S, Saini D, et al. Mucormycosis and COVID-19: An epidemic within a pandemic in India. Mycoses 2021; 64(10): 1253e60.
[24]
Palanisamy N, Vihari N, Meena DS, et al. Clinical profile of bloodstream infections in COVID-19 patients: A retrospective cohort study. BMC Infect Dis 2021; 21(1): 933.
[http://dx.doi.org/10.1186/s12879-021-06647-x] [PMID: 34496787]
[25]
Muthu V, Rudramurthy SM, Chakrabarti A, Agarwal R. Epidemiology and pathophysiology of COVID-19-associated mucormycosis: India versus the rest of the world. Mycopathologia 2021; 19: 1e16.
[26]
Navabshan I, Sakthivel B, Pandiyan R, et al. Computational lock and key and dynamic trajectory analysis of natural biophors against COVID-19 spike protein to identify effective lead molecules. Mol Biotechnol 2021; 63(10): 898-908.
[http://dx.doi.org/10.1007/s12033-021-00358-z] [PMID: 34159564]
[27]
Zia M, Goli M. Predisposing factors of important invasive fungal coinfections in COVID-19 patients: A review article. J Int Med Res 2021; 49(9): 3000605211043413.
[http://dx.doi.org/10.1177/03000605211043413] [PMID: 34494475]
[28]
WHO. Annex 1: 19th WHO model list of essential medicines 2015. Available from: https://www.who.int/medicines/publications/essentialmedicines/en/

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy